Resources
122 Results (showing 31 - 40)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 3/7/2023 (updated 3/27/2024)
Although pregnancy is motivation for opioid use disorder treatment, there is a risk of relapsing after childbirth. Unpacking Perinatal Experiences with Opioid Use Disorder: Relapse Risk Implications studies the perinatal experiences that can inform clinical social workers and other health/behavioral health providers on when and how to provide support during this time period.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 1/9/2023 (updated 3/27/2024)
The CDC report released in September 2022 highlights that more than 80% of pregnancy-related deaths were preventable. Among key findings, the report finds that one of the leading underlying causes of pregnancy-related death includes mental health conditions related to substance use disorder.
Posted 10/25/2022 (updated 3/27/2024)
The U.S. Government Accountability Office (GAO) published a new report to Congress on access to obstetric care in rural communities. GAO found that the number of rural hospitals providing obstetric services declined from 2004 through 2018. By 2018 more than half of rural counties lacked OB services. OB closures were focused in rural counties that were sparsely populated, had a majority of Black residents, and were considered low income. GAO interviewed stakeholders to identify the most important factors affecting availability of OB care and the efforts federal agencies, states, and others could take to increase availability of services.
Posted 9/6/2022 (updated 3/27/2024)
On Monday, the U.S. Department of Health & Human services announced approximately $4 million to four awardees through its Rural Maternity and Obstetrics Management Strategies Program to enhance access to and coordination of obstetric and maternal care in rural communities.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.